This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
protein
product name :
Human URG4 (aa 404-527) Control Fragment Recombinant Protein
catalog :
RP-92684
quantity :
100 uL
price :
US 259.00
product information
Product Type :
Protein
Product Name :
Human URG4 (aa 404-527) Control Fragment Recombinant Protein
Catalog # :
RP-92684
Quantity :
100 uL
Price :
US 259.00
Clonality :
Recombinant
Purity :
purified
Reactivity :
Human
Applications :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Species :
Human
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
The specific function of this protein remains unknown. URG4 is upregulated in the presence of hepatitis B virus (HBV)-encoded X antigen (HBxAg) and may contribute to the development of hepatocellular carcinoma by promoting hepatocellular growth and survival (Tufan et al., 2002 ).
Format :
Liquid
Applications w/Dilutions :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Aliases :
2010005J08Rik; 9130001I21Rik; AW060359; DKFZp666G166; DKFZp686O0457; HBV X protein up-regulated gene 4 protein; HBV X protein up-regulated gene 4 protein homolog; HBxAg up-regulated gene 4 protein; HBxAg up-regulated gene 4 protein homolog; KIAA1507; mKIAA1507; protein URG4; RGD1564681; up-regulated gene 4; upregulator of cell proliferation; up-regulator of cell proliferation; URG4; Urgcp
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments